Patents by Inventor MARTINE LATTA-MAHIEU

MARTINE LATTA-MAHIEU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VARIANT RNAi AGAINST ALPHA-SYNUCLEIN
    Publication number: 20210309999
    Abstract: Provided herein are RNAi molecules for treating neurodegenerative synucleinopathies. In some embodiments, the RNAi molecules target expression of alpha-synuclein (SNCA). Further provided herein are expression constructs, vectors (e.g rAAV), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat neurodegenerative synucleinopathies including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.
    Type: Application
    Filed: August 2, 2019
    Publication date: October 7, 2021
    Applicant: Genzyme Corporation
    Inventors: Bradford ELMER, Brenda RICHARDS, Martine LATTA-MAHIEU, Maria Carmen OBINU, Véronique TAUPIN, Véronique BLANCHARD
  • RECOMBINANT VIRUSES EXPRESSING LECITHIN-CHOLESTEROL ACYLTRANSFERASE, AND USES THEREOF IN GENE THERAPY
    Publication number: 20010014319
    Abstract: Defective recombinant viruses containing an inserted gene coding for all or part of lecithin-cholesterol acyltransferase (LCAT) or a variant thereof, pharmaceutical compositions containing said viruses, and the use thereof for treating or preventing dyslipoproteinaemia-related diseases, are disclosed.
    Type: Application
    Filed: November 5, 1997
    Publication date: August 16, 2001
    Applicant: RHONE-POULENC RORER S.A.
    Inventors: PATRICE DENEFLE, NICOLAS DUVERGER, MARTINE LATTA-MAHIEU, SANDRINE SEGURET